The role of IL-6 in the diminished CYP3A-mediated clearance of drugs in rheumatoid arthritis has been documented in clinical trials of monoclonal antibodies targeting IL-6 [415,416,417]. The gene discussed is IL6; the disease is rheumatoid arthritis.